Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

Thousands of 3D protein structures locked up in big-pharma vaults will be used to create a new AI tool that won’t be open to ...

Based on Intelligencia AI’s comprehensive, proprietary database of over 20,000 industry-sponsored, interventional oncology clinical programs (around 12,400 clinical trials), recent insights highlight ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

CARGO Therapeutics slashes workforce, halts drug development after a failed trial, with plans for a potential reverse merger.

The future of American drug innovation is threatened by US regulations that permit knockoff versions of new drugs to be sold ...